Avidity Biosciences, INC

Atrium Therapeutics reported Q2 2026 results, highlighting FDA IND clearance for ATR 1072, initiation of the Corventis trial, and a $15 million milestone payment from Bristol Myers Squibb.

Atrium Therapeutics has received FDA clearance for its Investigational New Drug application, enabling the Corventis Phase 1/2 clinical trial for ATR 1072 to treat PRKAG2 syndrome.

Novartis AG has completed its acquisition of Avidity Biosciences, Inc. for $72.00 per share in cash, following a pre-merger spin-off of Avidity's early-stage cardiology programs into Atrium Therapeutics, Inc.

Avidity Biosciences stockholders overwhelmingly approved the merger agreement with Novartis AG and the separation agreement for Atrium Therapeutics, satisfying a key transaction condition.

Avidity Biosciences has adjourned its special stockholder meeting to February 26, 2026, to finalize conditions for the SpinCo distribution, with the Novartis merger now expected to close on February 27, 2026.

Avidity Biosciences announced February 12, 2026, as the record date for the pro rata distribution of Atrium Therapeutics shares to stockholders, preceding its acquisition by Novartis AG.

Atrium Therapeutics, Inc. (Atrium) reported its financial results for the second quarter ended June 30, 2026, highlighting progress in its RNA delivery platform and advancing its lead product candidates for cardiomyopathies.

Avidity Biosciences announces its acquisition by Novartis AG for $72.00 per share in cash, alongside a spin-off of its early-stage cardiology programs.

Avidity Biosciences, Inc. reported a significant increase in net loss for the first half of 2025, driven by higher R&D and G&A expenses, while advancing three key RNA therapeutic programs into late-stage clinical trials.

Avidity Biosciences reports a net loss of $115.8 million for Q1 2025 and provides updates on its clinical programs and pipeline advancements.

Avidity Biosciences reports a strong cash position of $1.6 billion and advancements in its clinical programs for myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy in its Q3 2024 filing.

Avidity Biosciences reports a net loss of $139.6 million for the first six months of 2024, alongside significant cash and marketable securities growth to $1.3 billion.

Avidity Biosciences reports significant clinical advancements for its AOC pipeline, including positive del-zota data and FDA designations, alongside a pending merger with Novartis AG and a spin-off of its early-stage cardiology programs.

Avidity Biosciences highlights positive clinical data across its DM1, FSHD, and DMD programs and anticipates a BLA submission for del-zota in DMD44 by year-end 2025.

Avidity Biosciences has entered into a strategic collaboration with Bristol Myers Squibb, including a \$40 million equity investment, to advance cardiovascular therapeutics using its AOC platform.

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, disposed of common stock and stock options following the merger agreement with Novartis AG.

Avidity Biosciences director Tamar Thompson disposed of common stock and stock options on February 27, 2026, as part of the previously announced merger agreement with Novartis AG.

Avidity Biosciences' CFO, Michael F. MacLean, disposed of all common stock and stock options following the company's acquisition by Novartis AG.

Avidity Biosciences Director Simona Skerjanec disposed of all her common stock and stock options as part of the merger agreement with Novartis AG.

Avidity Biosciences' Chief Medical Officer disposed of all common stock and stock options following the company's acquisition by Novartis AG for $72.00 per share.

Avidity Biosciences' President and CEO, Sarah Boyce, disposed of all her common stock and stock options as part of the acquisition by Novartis AG.

Avidity Biosciences has adjourned its Special Stockholder Meeting to February 26, 2026, to finalize conditions for its SpinCo distribution, a prerequisite for the expected February 27, 2026 merger closing with Novartis.

Novartis AG plans to acquire Avidity Biosciences, Inc., which will first spin off its early-stage precision cardiology programs into a new independent entity, Atrium Therapeutics, Inc.

Novartis AG plans to acquire Avidity Biosciences, Inc., while Avidity's early-stage precision cardiology programs will be spun off into a new independent entity, Atrium Therapeutics, Inc.

Avidity Biosciences, Inc. announced early termination of the HSR waiting period for its merger with Novartis AG and accelerated executive compensation to mitigate tax impacts.

Novartis AG plans to acquire Avidity Biosciences for $12 billion, with Avidity spinning off its early-stage precision cardiology programs into a new independent entity, SpinCo.

Novartis AG will acquire Avidity Biosciences' neuroscience pipeline and RNA platform, while Avidity's early-stage cardiology programs will be spun off into a new independent company.

RTW Investments, LP and Roderick Wong have reduced their beneficial ownership in Avidity Biosciences, Inc. to 3.1%, falling below the 5% threshold.

RA Capital Management and its affiliates have reported a 0% beneficial ownership stake in Avidity Biosciences, Inc. as of March 31, 2026.

Janus Henderson Group plc has reported a reduction in its beneficial ownership of Avidity Biosciences, Inc. common stock to 4.6% as of December 31, 2025.

T. Rowe Price Associates, Inc. has filed an Amendment No. 8 to Schedule 13G, reporting a 0.1% beneficial ownership in Avidity Biosciences Inc.

Avoro Capital Advisors LLC and Behzad Aghazadeh have disclosed a 5.54% beneficial ownership stake in Avidity Biosciences, Inc. common stock.

Wellington Management Group LLP and its affiliates reported a passive beneficial ownership of 0.48% of Avidity Biosciences, Inc. common stock.

Janus Henderson Group plc has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 5.5% in Avidity Biosciences, Inc. common stock.